These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11817254)

  • 1. [Androgen therapy from the viewpoint of the internal medicine physician].
    Gasser RW
    Wien Med Wochenschr; 2001; 151(18-20):444-7. PubMed ID: 11817254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone and body functions.
    Köhn FM
    Aging Male; 2006 Dec; 9(4):183-8. PubMed ID: 17178552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone in older men after the Institute of Medicine Report: where do we go from here?
    Harman SM
    Climacteric; 2005 Jun; 8(2):124-35. PubMed ID: 16096168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Testosterone substitution in patients with hypogonadism].
    Martínez Portillo FJ; Cueva Martínez A; Martin Braun P; Fernández Arancibia MI; Jünemann KP; Alken P
    Arch Esp Urol; 2002 Sep; 55(7):827-38. PubMed ID: 12380312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dark side of testosterone deficiency: III. Cardiovascular disease.
    Traish AM; Saad F; Feeley RJ; Guay A
    J Androl; 2009; 30(5):477-94. PubMed ID: 19342698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Androgen deficit and diabetes].
    Cáp J
    Vnitr Lek; 2012 Mar; 58(3):228-31. PubMed ID: 22486290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgens, insulin resistance and vascular disease in men.
    Kapoor D; Malkin CJ; Channer KS; Jones TH
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):239-50. PubMed ID: 16117808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance.
    Traish AM; Saad F; Guay A
    J Androl; 2009; 30(1):23-32. PubMed ID: 18772488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects.
    Schubert M; Jockenhövel F
    J Endocrinol Invest; 2005; 28(3 Suppl):23-7. PubMed ID: 16042356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
    Miner M; Canty DJ; Shabsigh R
    Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids.
    Dayal M; Sammel MD; Zhao J; Hummel AC; Vandenbourne K; Barnhart KT
    J Womens Health (Larchmt); 2005 Jun; 14(5):391-400. PubMed ID: 15989411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypogonadism and metabolic syndrome: implications for testosterone therapy.
    Makhsida N; Shah J; Yan G; Fisch H; Shabsigh R
    J Urol; 2005 Sep; 174(3):827-34. PubMed ID: 16093964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Should older men be treated with testosterone?].
    Svartberg J
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):879-82. PubMed ID: 15815734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone supplementation: what and how to give.
    Jockenhövel F
    Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
    Swerdloff RS; Wang C
    Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.